PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29228585-11	2017	The supernatant concentrations of IL-1beta in the DV and T2DM groups were higher than those in the control group, and treatment with AG490 decreased the IL-1beta concentration.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	133-138	interleukin 1 beta	Homo sapiens	153-161	
21365246-7	2011	The activation of FUT1, FUT2 and FUT4 by IL-1beta is through the NF-kappaB pathway and the down-regulation of FUT3 and FUT5 by IL-6 is through the gp130/STAT-3 pathway, since they are inhibited specifically by panepoxydone and AG490, respectively.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	227-232	interleukin 1 beta	Homo sapiens	41-49	
21468922-7	2011	The JAK2 inhibitor (AG490) blocked STAT1/2 activation as well as MMP-13 induction in IL-1beta-treated SW1353 cells.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	20-25	interleukin 1 beta	Homo sapiens	85-93	
16354768-6	2006	Moreover, the JAK2 inhibitor alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide (AG-490) abolished PA-induced IL-1beta and IL-6 release but not TNF-alpha production, which is consistent with the notion that IL-1beta and IL-6 but not TNF-alpha contain a STAT binding element in their promoter region.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	29-74	interleukin 1 beta	Homo sapiens	105-113	
16354768-6	2006	Moreover, the JAK2 inhibitor alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide (AG-490) abolished PA-induced IL-1beta and IL-6 release but not TNF-alpha production, which is consistent with the notion that IL-1beta and IL-6 but not TNF-alpha contain a STAT binding element in their promoter region.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	29-74	interleukin 1 beta	Homo sapiens	202-210	
16354768-6	2006	Moreover, the JAK2 inhibitor alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide (AG-490) abolished PA-induced IL-1beta and IL-6 release but not TNF-alpha production, which is consistent with the notion that IL-1beta and IL-6 but not TNF-alpha contain a STAT binding element in their promoter region.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	76-82	interleukin 1 beta	Homo sapiens	105-113	
16354768-6	2006	Moreover, the JAK2 inhibitor alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide (AG-490) abolished PA-induced IL-1beta and IL-6 release but not TNF-alpha production, which is consistent with the notion that IL-1beta and IL-6 but not TNF-alpha contain a STAT binding element in their promoter region.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	76-82	interleukin 1 beta	Homo sapiens	202-210	
21190604-0	2010	[The effect of Janus kinase 2 inhibitor AG490 on renal tubular epithelial-myofibroblast transdifferentiation induced by interleukin-1beta].	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	40-45	interleukin 1 beta	Homo sapiens	120-137	
21190604-1	2010	OBJECTIVE: To investigate the effect of AG490, a Janus kinase 2 inhibitor, on epithelial-myofibroblast transdifferentiation induced by interleukin-1beta (IL-1beta).	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	40-45	interleukin 1 beta	Homo sapiens	135-152	
21190604-1	2010	OBJECTIVE: To investigate the effect of AG490, a Janus kinase 2 inhibitor, on epithelial-myofibroblast transdifferentiation induced by interleukin-1beta (IL-1beta).	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	40-45	interleukin 1 beta	Homo sapiens	154-162	
21190604-7	2010	The administration of AG490 could restore the expression of CK-18 (24 hours: 1.07+-0.07, 48 hours: 0.93+-0.06, 72 hours: 0.83+-0.06), and inhibit the expression of alpha-SMA induced by IL-1beta (24 hours: 0.33+- 0.01, 48 hours: 0.52+-0.01, 72 hours: 0.61+-0.04).	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	22-27	interleukin 1 beta	Homo sapiens	185-193	
17982107-3	2007	In this study, we report that the induction of PGHS-2 by IL-1beta is dramatically enhanced and prolonged when Jak2 signaling is abrogated, either with the specific inhibitor AG490 or by transiently transfecting fibroblasts with a dominant negative mutant Jak2.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	174-179	interleukin 1 beta	Homo sapiens	57-65